"Rule 59G-1.010(7) of the Florida Administrative Code (the “Medicaid Ban”) eliminates Florida Medicaid coverage for critical, medically necessary, evidence-based treatments for gender dysphoria. Denying coverage for such care effectively denies access to it for Florida Medicaid recipients who meet the requisite medical criteria, putting them at risk of significant harm. The basis for the Medicaid Ban, the Division of Florida Medicaid’s June 2, 2022 “Generally Accepted Professional Medical Standards Determination on the Treatment of Gender Dysphoria” (the “GAPMS Report”), mischaracterizes the professionally-accepted medical guidelines for treating gender dysphoria and the guidelines’ supporting evidence. Below, amici provide the Court with an accurate description of these treatment guidelines and summarize the scientific evidence supporting the medical interventions prohibited by the Medicaid Ban. While the Medicaid Ban affects all patients who are receiving treatment for gender dysphoria, this brief focuses primarily on the experience of transgender adolescents."
Read the Brief
We rely on your voice to advocate for our policy priorities. Join us to show our strength as a community that cares about endocrinology. Contact your US representatives or European Members of Parliament through our online platform. Take action and make a difference today.
